Prolia (Denosumab) Safety in Adults 65 and Older

Denosumab is a fully human monoclonal antibody that binds RANKL and blocks osteoclast formation. It is sold under the brand name Prolia at 60 mg by subcutaneous injection every 6 months for osteoporosis, and under the brand name Xgeva at a different dose and schedule (120 mg monthly) for cancer-related bone disease. This article addresses Prolia, the osteoporosis formulation, in adults aged 65 and older. It does not address Xgeva dosing or oncology use.

Prolia is FDA-approved for postmenopausal osteoporosis at high fracture risk, for increasing bone mass in men with osteoporosis at high fracture risk, and for bone loss associated with certain cancer treatments and glucocorticoid therapy. Most people who take it are older adults, since fracture risk rises with age.

The useful safety question for this age group is not whether denosumab works in older patients, since trial and registry data both say it does, but whether the prescriber and patient have an explicit plan for what happens when a dose is missed or the drug is stopped. Unplanned discontinuation is the one denosumab-specific harm in geriatric care that is common, serious, and preventable, and it is different in kind from the drug's other risks (hypocalcemia, infection, rare bone complications), which are manageable with monitoring rather than avoidable only by planning ahead.

What is established, what is plausible, and what is not established

• Established: Denosumab reduces vertebral, hip, and nonvertebral fractures in postmenopausal women, including women in their 70s and 80s, based on the original FREEDOM randomized trial and its long-term extension. Denosumab requires no dose adjustment for kidney function at any stage, including dialysis, because it is cleared by the reticuloendothelial system rather than the kidney. Stopping denosumab without a bisphosphonate transition plan is associated with rebound bone turnover and case reports of multiple vertebral fractures within roughly 1 to 2 years of the last dose.
• Plausible but not firmly established: A modest increase in serious infections (cellulitis, urinary tract infections) was seen in the pivotal trial population, but subsequent reviews have not settled whether this reflects a true drug effect or chance. Hypocalcemia risk in older adults with reduced kidney function is biologically expected and supported by case reports, but the exact monitoring interval that best prevents symptomatic hypocalcemia has not been established by a dedicated trial.
• Not established: A precise numeric comparison of fracture-reduction effect size across denosumab, zoledronic acid, and oral bisphosphonates specifically in patients 75 and older has not been confirmed by a head-to-head trial in this exact age band; available comparisons come from subgroup analyses, registries, and non-head-to-head trials, which is a lower tier of evidence than a dedicated randomized comparison.

Specific numeric claims below (percentages, confidence intervals, incidence rates) originate in named trials and reviews. Because this draft could not independently re-verify each cited identifier against the original paper, any number used in an individual clinical decision should be checked against the primary publication or current FDA label before being relied upon.

Why denosumab is commonly chosen for older patients

Denosumab avoids the gastrointestinal handling problems of oral bisphosphonates (no fasting requirement, no need to remain upright, no esophageal irritation risk), which makes it a practical option for patients with swallowing difficulty, esophageal disease, or cognitive impairment that complicates dosing instructions. It also avoids the renal dose thresholds that limit bisphosphonate use in older adults with reduced kidney function, discussed below.

The FREEDOM trial, the pivotal randomized study behind the osteoporosis approval, enrolled postmenopausal women with a mean age in the low 70s and reported a large reduction in new vertebral fractures over three years compared with placebo, with overall adverse event rates similar between groups. A long-term open-label extension of the same cohort reported continued low fracture incidence and continued bone density gains through roughly a decade of treatment, without the density plateau typically seen with oral bisphosphonates after several years. Clinical practice guidelines from major endocrine societies list denosumab as a first-line option for postmenopausal women at high fracture risk, particularly when oral bisphosphonates are contraindicated or not tolerated.

A separate line of evidence addresses men with osteoporosis, a population that is disproportionately older and under-treated. A comparative analysis of denosumab, zoledronic acid, and alendronate in men with osteoporosis found each agent produced measurable improvements in bone mineral density and trabecular bone score, without a clearly superior single agent across all measures (Chandran et al., 2026). This supports treating men over 65 as a population with real treatment options rather than an afterthought to postmenopausal osteoporosis data, but it does not establish that any one drug is safer than another specifically in men over 75; that comparison requires further confirmation.

Does efficacy hold up in the oldest patients?

Age-stratified analyses of the FREEDOM population have reported that fracture risk reduction with denosumab remained statistically significant across age bands, including patients 75 and older, without a clear loss of effect in the oldest group. Registry-based observational data from outside the trial setting have also reported reduced hip fracture rates in denosumab-treated women in their 80s compared with untreated matched controls, with a smaller effect size than seen in the randomized trial, which is expected since real-world adherence and baseline health differ from a trial population. Both findings are worth verifying against their primary sources before quoting an exact percentage to a patient or in a clinical note, since this draft did not carry forward specific unverified identifiers for these analyses.

Decision framework: what changes management in a patient 65 or older

The one scenario this framework treats as an outright error, at any age, is stopping denosumab with no plan at all. Continuing treatment or transitioning to a bisphosphonate are both reasonable; unplanned discontinuation is not.

Kidney function: an advantage with one important caveat

Kidney function declines with age, and by the early 70s many patients have an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m², placing them in chronic kidney disease (CKD) stage 3 or beyond. Zoledronic acid is contraindicated below an eGFR of roughly 35 mL/min, and oral bisphosphonates carry cautions near similar thresholds. Denosumab has no such renal contraindication and can be used at full dose across all CKD stages, including dialysis, because it is not renally excreted.

The tradeoff is hypocalcemia. The FDA label for Prolia carries a warning about severe, symptomatic hypocalcemia in patients with CKD stage 4 or 5, particularly those on dialysis as noted in FDA prescribing information. Case reports describe symptomatic hypocalcemia requiring intravenous calcium in dialysis patients who received denosumab without adequate vitamin D repletion beforehand. The standard approach before a first injection is to correct 25-hydroxyvitamin D to at least 30 ng/mL, ensure adequate dietary or supplemental calcium intake, and check serum calcium roughly 2 weeks after injection in patients with an eGFR below 30.

Infection risk: a real but unresolved signal

The pivotal trial reported a small increase in serious infections, mostly cellulitis and urinary tract infections requiring hospitalization, in the denosumab group compared with placebo. Subsequent systematic reviews have not resolved whether this represents a true drug effect or a chance finding given multiple comparisons across a large trial, and post-marketing safety reports have noted serious skin infections without establishing a definitive causal mechanism.

For an individual older patient, this uncertainty should be stated plainly rather than minimized: the infection signal is real enough to warrant attention in frail or immunocompromised patients, and small enough that it does not change the recommendation for most patients at high fracture risk, where the benefit of fracture prevention is large and well established. Patients and caregivers should know to report new cellulitis-like skin changes or urinary symptoms promptly rather than waiting for a routine visit.

The rebound vertebral fracture problem

This is the safety issue most specific to denosumab, and it is more consequential in older adults because they typically have less bone reserve and higher morbidity from new vertebral fractures. When denosumab is discontinued, bone turnover markers rise above pre-treatment levels within several months, and bone density can return toward baseline within roughly a year to eighteen months. Case series have documented patients sustaining multiple new vertebral fractures within this window after their last injection.

A position statement from the European Calcified Tissue Society addressed this directly, recommending against unplanned discontinuation and advising transition to a bisphosphonate, commonly a single intravenous zoledronic acid infusion, within roughly 6 months of the final denosumab dose. In geriatric practice this creates an obligation at the time treatment starts, not just at the time it stops: before beginning denosumab, clinicians should discuss the ongoing twice-yearly commitment, and identify in advance what happens if the patient becomes non-adherent, changes clinics, or transitions into a hospital or skilled nursing stay where the injection schedule could be interrupted.

Falls, polypharmacy, and practical dosing

The pivotal trial tracked falls as a secondary outcome and did not find a difference between denosumab and placebo groups. Denosumab is not metabolized by cytochrome P450 enzymes and has no known pharmacokinetic interactions with warfarin, direct oral anticoagulants, statins, or common antihypertensives, which is a genuine advantage in patients on multiple medications. Older adults commonly take five or more prescription drugs (CDC NCHS Data Brief 347), and adding a drug with no known interaction profile reduces both monitoring burden and interaction risk.

The subcutaneous injection can be given by a nurse or trained caregiver in the upper arm, thigh, or abdomen, which makes it practical for homebound patients or those in long-term care. There is no requirement for extended post-injection observation in patients without a prior history of hypocalcemia.

Osteonecrosis of the jaw and atypical femoral fracture

Both complications are rare at osteoporosis doses and receive attention disproportionate to their frequency. Long-term extension data from the pivotal trial cohort reported osteonecrosis of the jaw in a small number of patients over a decade of continuous use, and a professional position paper on medication-related osteonecrosis of the jaw considers the risk with denosumab at osteoporosis dosing comparable to that seen with oral bisphosphonates, recommending routine dental care rather than drug avoidance. Atypical femoral fractures have been reported even less frequently with denosumab than with bisphosphonates, plausibly because denosumab's effect clears from the body within several months of the last dose rather than accumulating in bone matrix.

The practical message for older patients: continue routine dental care, do not delay necessary dental procedures for fear of the drug, and report new or unusual thigh or groin pain. Neither complication should by itself be a reason to withhold treatment from a patient at genuinely high fracture risk.

Deprescribing near the end of life

Whether to continue osteoporosis treatment in a very old or frail patient with a limited life expectancy is a legitimate clinical judgment call, not a fixed rule. The rebound risk described above means denosumab cannot simply be stopped the way a bisphosphonate drug holiday can. If treatment is stopped, a single intravenous zoledronic acid dose given around 6 months after the last denosumab injection is the commonly recommended way to blunt the rebound. For patients where even a single infusion is judged inappropriate given goals of care, continuing low-burden twice-yearly denosumab injections until death is a reasonable alternative, since the injections themselves require little monitoring in patients with normal kidney function.

Abrupt discontinuation with no plan at all is the option this evidence base consistently argues against, regardless of age or frailty.